Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan 3;12(1):1.
doi: 10.1186/s13014-016-0740-5.

Current status and perspectives of interventional clinical trials for glioblastoma - analysis of ClinicalTrials.gov

Nikola Cihoric  1 , Alexandros Tsikkinis  2 , Giuseppe Minniti  3 , Frank J Lagerwaard  4 , Ulrich Herrlinger  5 , Etienne Mathier  6 , Ivan Soldatovic  7 , Branislav Jeremic  8 , Pirus Ghadjar  9 , Olgun Elicin  6 , Kristina Lössl  6 , Daniel M Aebersold  6 , Claus Belka  10   11 , Evelyn Herrmann  6 , Maximilian Niyazi  10   11
Affiliations
Review

Current status and perspectives of interventional clinical trials for glioblastoma - analysis of ClinicalTrials.gov

Nikola Cihoric et al. Radiat Oncol. .

Abstract

The records of 208.777 (100%) clinical trials registered at ClinicalTrials.gov were downloaded on the 19th of February 2016. Phase II and III trials including patients with glioblastoma were selected for further classification and analysis. Based on the disease settings, trials were classified into three groups: newly diagnosed glioblastoma, recurrent disease and trials with no differentiation according to disease setting. Furthermore, we categorized trials according to the experimental interventions, the primary sponsor, the source of financial support and trial design elements. Trends were evaluated using the autoregressive integrated moving average model. Two hundred sixteen (0.1%) trials were selected for further analysis. Academic centers (investigator initiated trials) were recorded as primary sponsors in 56.9% of trials, followed by industry 25.9%. Industry was the leading source of monetary support for the selected trials in 44.4%, followed by 25% of trials with primarily academic financial support. The number of newly initiated trials between 2005 and 2015 shows a positive trend, mainly through an increase in phase II trials, whereas phase III trials show a negative trend. The vast majority of trials evaluate forms of different systemic treatments (91.2%). In total, one hundred different molecular entities or biologicals were identified. Of those, 60% were involving drugs specifically designed for central nervous system malignancies. Trials that specifically address radiotherapy, surgery, imaging and other therapeutic or diagnostic methods appear to be rare. Current research in glioblastoma is mainly driven or sponsored by industry, academic medical oncologists and neuro-oncologists, with the majority of trials evaluating forms of systemic therapies. Few trials reach phase III. Imaging, radiation therapy and surgical procedures are underrepresented in current trials portfolios. Optimization in research portfolio for glioblastoma is needed.

Keywords: Clinicaltrials.gov; Glioblastoma; Interventional Clinical Trials.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Trials selection process diagram
Fig. 2
Fig. 2
Trials Primary Sponsors (a) and Probable Source of Monetary Support (b)
Fig. 3
Fig. 3
Systemic therapy
Fig. 4
Fig. 4
New trials per year. Panel a shows ARIMA forecast model for all evaluated trials. Panel b shows ARIMA forecast model for phase II trials only
See this image and copyright information in PMC

References

    1. Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol. 2003;30(6 Suppl 19):10–14. doi: 10.1053/j.seminoncol.2003.11.031. - DOI - PubMed
    1. Curran WJ, Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85(9):704–710. doi: 10.1093/jnci/85.9.704. - DOI - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. doi: 10.1056/NEJMoa043330. - DOI - PubMed
    1. Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Le Pechoux C, Auperin A, Le Chevalier T, Stephens RJ, Arriagada R, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev. 2015;3:CD011430. - PMC - PubMed
    1. Wollmann G, Ozduman K, van den Pol AN. Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J. 2012;18(1):69–81. doi: 10.1097/PPO.0b013e31824671c9. - DOI - PMC - PubMed